National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Imiquimod 3.75%(Zyclara®) indicated for topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.

 Rapid Review

Commenced Completed Outcome
10/09/2013 18/09/2013 Full Pharmacoeconomic Evaluation not recommended